Onco-Innovations Targets DNA Repair with Novel PNKP Inhibitor

Onco-Innovations Limited, a Canadian-based oncology company, was featured in a BioMedWire editorial examining the rapidly expanding DNA Damage Response inhibitor market, where new drug classes are emerging beyond PARP inhibitors. The company is advancing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple DNA repair pathways. According to the editorial, Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology and is positioning itself as an early leader in a novel class of cancer therapeutics. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) highlighted preclinical data showing ONC010 more than doubled median survival in PTEN-deficient colorectal cancer animal models while demonstrating a favorable toxicity profile. The editorial also noted the company’s progress in manufacturing scale-up, IND-enabling studies and planned first-in-human clinical development, supported by its proprietary SynoGraph(TM) causal AI platform through subsidiary Inka Health. The feature additionally reviewed recent developments across the oncology and biotechnology sectors involving AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD) and Foghorn Therapeutics Inc. (NASDAQ: FHTX).

Onco-Innovations is dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The Company has secured an exclusive worldwide license to patented technology that targets solid tumours. The editorial underscores that Onco-Innovations is advancing a next-generation approach that could potentially shift the treatment landscape for cancers resistant to current therapies. The company’s progress in preclinical studies and manufacturing scale-up suggests it is moving steadily toward clinical trials, with the BioMedWire feature highlighting its potential as a leader in the DNA Damage Response space. For more details, the full press release is available at https://ibn.fm/HH1VP.

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.